An evaluation of the emerging vaccines against influenza in children

BMC Public Health

Volumn 13, Issue SUPPL.3, 2013, Pages

  Nair, Harish ^a,b   Lau, Eva Shi May ^a   Brooks, W Abdullah ^c,d   Seong, Ang Choon ^a   Theodoratou, Evropi ^a   Zgaga, Lina ^a   Huda, Tanvir ^c   Jadhav, Suresh S ^e   Rudan, Igor ^a   Campbell, Harry ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^c INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e Indus Biotech Private Limited   (India)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NEW DRUG;

CHILD; DEVELOPING COUNTRY; DISEASE OUTBREAKS; HUMAN; INFANT; INFLUENZA, HUMAN; PANDEMICS; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTIONS; STATISTICS AND NUMERICAL DATA; VACCINATION;

CHILD; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; DISEASE OUTBREAKS; DRUGS, INVESTIGATIONAL; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; RESPIRATORY TRACT INFECTIONS; VACCINATION;

EID: 84884406782     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-13-S3-S14     Document Type: Review

References (91)

1. Epidemiology and etiology of childhood pneumonia. Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H, Bull World Health Organ 2008 86 5 408 416 10.2471/BLT.07.048769 18545744
2. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, Rudan I, Campbell H, Cibulskis R, Li M, et al. Lancet 2012 379 9832 2151 2161 10.1016/S0140-6736(12)60560-1 22579125
3. Viral pneumonia. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR, Lancet 2011 377 9773 1264 1275 10.1016/S0140-6736(10)61459-6 21435708
4. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. Neuzil KM, Zhu YW, Griffin MR, Edwards KM, Thompson JM, Tollefson SJ, Wright PF, J Infect Dis 2002 185 2 147 152 10.1086/338363 11807687 (Pubitemid 34056437)
5. The underrecognized burden of influenza in young children. Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, Bridges CB, Grijalva CG, Zhu YW, Bernstein DI, et al. N Engl J Med 2006 355 1 31 40 10.1056/NEJMoa054869 16822994
6. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, Simmerman JM, Gordon A, Sato M, Howie S, et al. Lancet 2011 378 9807 1917 1930 10.1016/S0140-6736(11)61051-9 22078723
7. Influenza is a major contributor to childhood pneumonia in a tropical developing country. Brooks WA, Goswami D, Rahman M, Nahar K, Fry AM, Balish A, Iftekharuddin N, Azim T, X X, Klimov A, et al. Pediatr Infect Dis J 2010 29 3 216 221 10.1097/INF.0b013e3181bc23fd 20190613
8. Socioeconomic impact of influenza on healthy children and their families. Principi N, Esposito S, Marchisio P, Gasparini R, Crovari P, Pediatr Infect Dis J 2003 22 10 Suppl 207 210 14551476
9. State of the art of vaccine research and development. Initiative for Vaccines Research Team, Geneva: World Health Organization, Department of Immunization VaB, 2005 14 17
10. A global pandemic influenza vaccine action plan. Kieny MP, Costa A, Hombach J, Carrasco P, Pervikov Y, Salisbury D, Greco M, Gust I, LaForce M, Franco-Paredes C, et al. Vaccine 2006 24 40-41 6367 6370 10.1016/j.vaccine.2006. 07.021 17240560 (Pubitemid 44348913)
11. An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children. Higginson D, Theodoratou E, Nair H, Huda T, Zgaga L, Jadhav SS, Omer SB, Rudan I, Campbell H, BMC public health 2011 11 Suppl 3 31 10.1186/1471-2458-11-S3-S31 21501450
12. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children. Nair H, Verma VR, Theodoratou E, Zgaga L, Huda T, Simoes EA, Wright PF, Rudan I, Campbell H, BMC public health 2011 11 Suppl 3 30 10.1186/1471-2458-11-S3-S30 21501449
13. An evaluation of emerging vaccines for childhood meningococcal disease. Choudhuri D, Huda T, Theodoratou E, Nair H, Zgaga L, Falconer R, Luksic I, Johnson HL, Zhang JS, El Arifeen S, et al. BMC public health 2011 11 Suppl 3 29 10.1186/1471-2458-11-S3-S29 21501447
14. An evaluation of oxygen systems for treatment of childhood pneumonia. Catto AG, Zgaga L, Theodoratou E, Huda T, Nair H, El Arifeen S, Rudan I, Duke T, Campbell H, BMC public health 2011 11 Suppl 3 28 10.1186/1471-2458-11-S3-S28 21501446
15. An evaluation of the emerging vaccines and immunotherapy against staphylococcal pneumonia in children. Huda T, Nair H, Theodoratou E, Zgaga L, Fattom A, El Arifeen S, Rubens C, Campbell H, Rudan I, BMC public health 2011 11 Suppl 3 27 10.1186/1471-2458-11-S3-S27 21501445
16. An evaluation of emerging vaccines for childhood pneumococcal pneumonia. Webster J, Theodoratou E, Nair H, Seong AC, Zgaga L, Huda T, Johnson HL, Madhi S, Rubens C, Zhang JS, et al. BMC public health 2011 11 Suppl 3 26 10.1186/1471-2458-11-S3-S26 21501444
17. Setting priorities in global child health research investments: guidelines for implementation of CHNRI method. Rudan I, Gibson JL, Ameratunga S, El Arifeen S, Bhutta ZA, Black M, Black RE, Brown KH, Campbell H, Carneiro I, et al. Croat Med J 2008 49 6 720 733 10.3325/cmj.2008.49.720 19090596
18. The complex challenge of setting priorities in health research investments. Rudan I, Indian J Med Res 2009 129 4 351 353 19535827
19. Setting priorities in global child health research investments: universal challenges and conceptual framework. Rudan I, Chopra M, Kapiriri L, Gibson J, Ann Lansang M, Carneiro I, Ameratunga S, Tsai AC, Chan KY, Tomlinson M, et al. Croat Med J 2008 49 3 307 317 10.3325/cmj.2008.3.307 18581609 (Pubitemid 351955763)
20. Childhood pneumonia and diarrhoea: setting our priorities right. Rudan I, El Arifeen S, Black RE, Campbell H, Lancet Infect Dis 2007 7 1 56 61 10.1016/S1473-3099(06)70687-9 17182344 (Pubitemid 44917782)
21. Setting priorities in global child health research investments: assessment of principles and practice. Rudan I, Gibson J, Kapiriri L, Lansang MA, Hyder AA, Lawn J, Darmstadt GL, Cousens S, Bhutta ZA, Brown KH, et al. Croat Med J 2007 48 5 595 604 17948946 (Pubitemid 350022000)
22. Research priorities to reduce global mortality from newborn infections by 2015. Bahl R, Martines J, Ali N, Bhan MK, Carlo W, Chan KY, Darmstadt GL, Hamer DH, Lawn JE, McMillan DD, et al. Pediatr Infect Dis J 2009 28 1 Suppl 43 48 19106763
23. Setting research priorities to reduce global mortality from childhood diarrhoea by 2015. Fontaine O, Kosek M, Bhatnagar S, Boschi-Pinto C, Chan KY, Duggan C, Martinez H, Ribeiro H, Rollins NC, Salam MA, et al. PLoS Med 2009 6 3 41 10.1371/journal.pmed.1000041 19278292
24. Setting priorities in global child health research investments: addressing values of stakeholders. Kapiriri L, Tomlinson M, Chopra M, El Arifeen S, Black RE, Rudan I, Croat Med J 2007 48 5 618 627 17948948 (Pubitemid 350022002)
25. Setting priorities in child health research investments for South Africa. Tomlinson M, Chopra M, Sanders D, Bradshaw D, Hendricks M, Greenfield D, Black RE, El Arifeen S, Rudan I, PLoS Med 2007 4 8 259 10.1371/journal.pmed.0040259 17760497 (Pubitemid 47358162)
26. Setting priorities for global mental health research. Tomlinson M, Rudan I, Saxena S, Swartz L, Tsai AC, Patel V, Bull World Health Organ 2009 87 6 438 446 10.2471/BLT.08.054353 19565122
27. Research priorities for health of people with disabilities: an expert opinion exercise. Tomlinson M, Swartz L, Officer A, Chan KY, Rudan I, Saxena S, Lancet 2009 374 9704 1857 1862 10.1016/S0140-6736(09)61910-3 19944866
28. Setting priorities for development of emerging interventions against childhood pneumonia, meningitis and influenza. Rudan I, Theodoratou E, Zgaga L, Nair H, Chan KY, Tomlinson M, Tsai AC, Biloglav Z, Huda T, El Arifeen S, et al. J Glob Health 2012 2 1 10304 23198129
29. Report of the second WHO Consultation on the Global Action Plan for Influenza Vaccines (GAP). World Health Organisation, Geneva, Switzerland: World Health Organisation 2011
30. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, et al. BMJ 2010 340 2649 10.1136/bmj.c2649 20508026
31. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. Carter NJ, Plosker GL, BioDrugs 2008 22 5 279 292 10.2165/00063030-200822050-00001 18778110
32. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Drame M, Gillard P, van der Most R, Van Mechelen M, Hanon E, et al. Vaccine 2010 28 3 849 857 10.1016/j.vaccine.2009.10.017 19835828
33. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S, Clin Infect Dis 2010 51 9 997 1004 10.1086/656578 20868284
34. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A, J Infect Dis 2009 200 6 841 848 10.1086/605505 19673651
35. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N, Pediatr Infect Dis J 2012 31 5 494 500 10.1097/INF.0b013e31824bb179 22301476
36. Optaflu. http://www.emea.europa.eu/docs/en-GB/document-library/EPAR- Summary-for-the-public/human/000758/WC500046952.pdf
37. Celvapan. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Summary-for-the-public/human/000982/WC500022671.pdf
38. A review of production technologies for influenza virus vaccines, and their suitability for deployment in developing countries for influenza pandemic preparedness. World Health Organisation, Geneva: World Health Organisation, Initiative for Vaccine Research, 2006
39. Use of MDCK cells for production of live attenuated influenza vaccine. Liu J, S X, Schwartz R, Kemble G, Vaccine 2009 27 46 6460 6463 10.1016/j.vaccine.2009.06.024 19559113
40. NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. Zhou B, Li Y, Belser JA, Pearce MB, Schmolke M, Subba AX, Shi Z, Zaki SR, Blau DM, Garcia-Sastre A, et al. Vaccine 2010 28 50 8015 8025 10.1016/j.vaccine.2010. 08.106 20934458
41. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process. George M, Farooq M, Dang T, Cortes B, Liu J, Maranga L, Biotechnol Bioeng 2010 106 6 906 917 10.1002/bit.22753 20589670
42. Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. Baskin CR, Bielefeldt-Ohmann H, Garcia-Sastre A, Tumpey TM, Van Hoeven N, Carter VS, Thomas MJ, Proll S, Solorzano A, Billharz R, et al. J Virol 2007 81 21 11817 11827 10.1128/JVI.00590-07 17715226 (Pubitemid 47623814)
43. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vincent AL, Ma W, Lager KM, Janke BH, Webby RJ, Garcia-Sastre A, Richt JA, Vaccine 2007 25 47 7999 8009 10.1016/j.vaccine. 2007.09.019 17933442 (Pubitemid 350011004)
44. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Matassov D, Cupo A, Galarza JM, Viral Immunol 2007 20 3 441 452 10.1089/vim.2007.0027 17931114 (Pubitemid 47585318)
45. Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Weldon WC, Martin MP, Zarnitsyn V, Wang B, Koutsonanos D, Skountzou I, Prausnitz MR, Compans RW, Clin Vaccine Immunol 2011 18 4 647 654 10.1128/CVI.00435-10 21288996
46. Formulation development of a plant-derived h1n1 influenza vaccine containing purified recombinant hemagglutinin antigen. Iyer V, Liyanage MR, Shoji Y, Chichester JA, Jones RM, Yusibov V, Joshi SB, Middaugh CR, Hum Vaccin Immunother 2012 8 4 453 464 22370514
47. Plant-expressed HA as a seasonal influenza vaccine candidate. Shoji Y, Chichester JA, Bi H, Musiychuk K, de la Rosa P, Goldschmidt L, Horsey A, Ugulava N, Palmer GA, Mett V, et al. Vaccine 2008 26 23 2930 2934 10.1016/j.vaccine. 2008.03.045 18440103
48. Yeast expressed recombinant Hemagglutinin protein of novel H1N1 elicits neutralising antibodies in rabbits and mice. Athmaram TN, Saraswat S, Santhosh SR, Singh AK, Suryanarayana WS, Priya R, Gopalan N, Parida M, Rao PV, Vijayaraghavan R, Virol J 2011 8 524 10.1186/1743-422X-8-524 22126628
49. Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice. Liu G, Tarbet B, Song L, Reiserova L, Weaver B, Chen Y, Li H, Hou F, Liu X, Parent J, et al. PLoS One 2011 6 6 20928 10.1371/journal.pone.0020928 21687743
50. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok(R) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM, Vaccine 2011 29 12 2272 2278 10.1016/j.vaccine.2011.01.039 21277410
51. A fast track influenza virus vaccine produced in insect cells. Cox MM, Hashimoto Y, J Invertebr Pathol 2011 107 Suppl 31 41 21784229
52. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized, placebo-controlled trial. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M, Vaccine 2011 29 44 7733 7739 10.1016/j.vaccine.2011.07.128 21835220
53. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, et al. J Virol 2011 85 21 10945 10954 10.1128/JVI.05406-11 21865396
54. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. King JC Jr., Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P, Vaccine 2009 27 47 6589 6594 10.1016/j.vaccine.2009.08.032 19716456
55. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, et al. Vaccine 2011 29 44 7826 7834 10.1016/j.vaccine.2011.07.099 21816199
56. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. Stanekova Z, Kiraly J, Stropkovska A, Mikuskova T, Mucha V, Kostolansky F, Vareckova E, Acta Virol 2011 55 1 61 67 10.4149/av-2011-01-61 21434706
57. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Zhou D, Wu TL, Lasaro MO, Latimer BP, Parzych EM, Bian A, Li Y, Li H, Erikson J, Xiang Z, et al. Mol Ther 2010 18 12 2182 2189 10.1038/mt.2010.202 20877342
58. Press release. Dynavax Reports New Phase 1a and Phase 1b Data for Universal Flu Vaccine Candidate. http://investors.dynavax.com/releasedetail.cfm? ReleaseID=551606
59. VaxInnate's Universal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Clinical Study. http://www.vaxinnate.com/pages/pressreleases/20081026- 001.html
60. MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization. Kreijtz JH, Suezer Y, de Mutsert G, van Amerongen G, Schwantes A, van den Brand JM, Fouchier RA, Lower J, Osterhaus AD, Sutter G, et al. PLoS One 2009 4 11 7790 10.1371/journal.pone.0007790 19915662
61. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Lower J, Osterhaus AD, et al. Vaccine 2009 27 45 6296 6299 10.1016/j.vaccine.2009.03.020 19840663
62. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Rimmelzwaan GF, Sutter G, Expert Rev Vaccines 2009 8 4 447 454 10.1586/erv.09.4 19348560
63. The Multimeric Universal Influenza Vaccine: BVX-M001. http://www.biondvax.com/128084/Product
64. Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. Tang DC, Zhang J, Toro H, Shi Z, Van Kampen KR, Expert Rev Vaccines 2009 8 4 469 481 10.1586/erv.09.1 19348562
65. Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers. Johnson PV, Blair BM, Zeller S, Kotton CN, Hohmann EL, Microbiol Immunol 2011 55 5 304 317 10.1111/j.1348-0421.2011.00322.x 21338384
66. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Holman DH, Wang D, Raja NU, Luo M, Moore KM, Woraratanadharm J, Mytle N, Dong JY, Vaccine 2008 26 21 2627 2639 10.1016/j.vaccine.2008.02.053 18395306
67. AlphaVax announces results from initial testing of its H1N1 (swine) influenza vaccine. http://www.redorbit.com/news/health/1722686/alphavax- announces-results-from-initial-testing-of-its-h1n1-swine/
68. Our avian influenza (H5N1) vaccine candidate. http://paxvax.com/the- paxvax-solution/our-products
69. Vaxart Begins First Oral Vaccine Clinical Trial. http://www.vaxart.com/ files/VaxartPh1Trial.pdf
70. Vector Engineering. http://www.jenner.ac.uk/vector-engineering
71. Cytotoxicity and immunological responses following oral vaccination of nanoencapsulated avian influenza virus H5 DNA vaccine with green synthesis silver nanoparticles. Jazayeri SD, Ideris A, Zakaria Z, Shameli K, Moeini H, Omar AR, J Control Release 2012 161 1 116 123 10.1016/j.jconrel.2012.04.015 22549012
72. DNA / SnyCon w/ Electroporation Pipeline. http://www.inovio.com/products/ index.htm
73. NIAID Testing Candidate DNA Vaccine for 2009 H1N1 Influenza. http://www.niaid.nih.gov/news/newsreleases/2009/Pages/CandidateDNAvaccine.aspx
74. Vaccines for preventing influenza in healthy children. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E, Cochrane Database Syst Rev 2012 8 D004879 22895945
75. Influenza vaccine in healthy children: a meta-analysis. Negri E, Colombo C, Giordano L, Groth N, Apolone G, La Vecchia C, Vaccine 2005 23 22 2851 2861 10.1016/j.vaccine.2004.11.053 15780733 (Pubitemid 40386486)
76. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Zangwill KM, Belshe RB, Pediatr Infect Dis J 2004 23 3 189 197 10.1097/01.inf.0000116292.46143.d6 15014289 (Pubitemid 38332641)
77. Bharat Biotech launches first cell culture-based H1N1 vaccine in India. Kumar P, BioSpectrum (Asia Edition) 2011 5 26 27
78. 7th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. http://www.who.int/vaccine-research/diseases/influenza/meeting-17- 18Feb2011/en/index.html
79. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J, Vaccine 2009 27 7 1101 1110 10.1016/j.vaccine.2008.11.093 19095024
80. Medicago Successfully Completes the Production of More Than Ten Million Doses of H1N1 VLP Influenza Vaccine in One Month. http://www.medicago.com/ English/news/News-Releases/News-ReleaseDetails/2012/Medicago-Successfully- Completes-the-Production-of-More-Than-Ten-Million-Doses-of-H1N1-VLP-Influenza- Vaccine-in-One-Month11302/default.aspx
81. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Jones S, Evans K, McElwaine-Johnn H, Sharpe M, Oxford J, Lambkin-Williams R, Mant T, Nolan A, Zambon M, Ellis J, et al. Vaccine 2009 27 18 2506 2512 10.1016/j.vaccine.2009. 02.061 19368793
82. A role for Streptococcus pneumoniae in virus-associated pneumonia. Madhi SA, Klugman KP, Nature medicine 2004 10 8 811 813 10.1038/nm1077 15247911
83. Clinical impact of combined viral and bacterial infection in patients with community-acquired pneumonia. Johansson N, Kalin M, Hedlund J, Scandinavian journal of infectious diseases 2011 43 8 609 615 10.3109/00365548.2011.570785 21466255
84. A four-stage strategy to reduce childhood pneumonia-related mortality by 2015 and beyond. Brooks WA, Vaccine 2009 27 5 619 623 10.1016/j.vaccine.2008.10. 071 19010371
85. The introduction of new vaccines into developing countries. Mahoney RT, Maynard JE, Vaccine 1999 17 7-8 646 652 10.1016/S0264-410X(98)00246-1 10067669 (Pubitemid 29074717)
86. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Alarcon JB, Hartley AW, Harvey NG, Mikszta JA, Clin Vaccine Immunol 2007 14 4 375 381 10.1128/CVI.00387-06 17329444 (Pubitemid 46732547)
87. Vaccines for preventing influenza in healthy adults. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V, Cochrane Database Syst Rev 2007 2 D001269 17443504
88. Plant-made vaccines in support of the Millennium Development Goals. Penney CA, Thomas DR, Deen SS, Walmsley AM, Plant cell reports 2011 30 5 789 798 10.1007/s00299-010-0995-5 21243362
89. Influenza Vaccine Strategies for Broad Global Access- Key Findings and Project Methodology. Oliver Wyman, PATH 2007
90. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Collin N, de Radigues X, Vaccine 2009 27 38 5184 5186 10.1016/j.vaccine.2009.06.034 19563891
91. Effectiveness of influenza vaccination and its impact on health inequalities. Antunes JL, Waldman EA, Borrell C, Paiva TM, International journal of epidemiology 2007 36 6 1319 1326 10.1093/ije/dym208 17977871 (Pubitemid 350239001)